CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNUdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00610883
NCT00610883Phase 2Completed
CompareCT.gov

LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Feb 8, 2008·Updated Sep 28, 2023

In Brief

A Phase 2 clinical trial evaluating LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU for Non-Hodgkin's Lymphoma. Completed, enrolled 17 participants across 1 site.

Detailed Summary

Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts: * Induction ends on day 19 * Consolidation ends on day 38 or 42 * Maintenance may include up to 6 cycles

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 8, 2008
Enrollment StartMay 1, 1990
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 18.6 yearsPosted 18.4 years ago

Interventions

LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNUdrug

LSA4 intervention includes three phases: induction, consolidation and maintenance